Adamis Pharmaceuticals Stock Forecast, Price & News

+0.12 (+11.32 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume19.13 million shs
Average Volume2.77 million shs
Market Capitalization$175.69 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ADMP News and Ratings via Email

Sign-up to receive the latest news and ratings for Adamis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Adamis Pharmaceuticals logo

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's product candidates comprise Symjepi Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of fluticasone for the treatment of asthma; beclomethasone, a metered dose inhaler product for the asthma; and naloxone injection product candidates for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.47 out of 5 stars

Medical Sector

985th out of 2,219 stocks

Pharmaceutical Preparations Industry

473rd out of 869 stocks

Analyst Opinion: 3.0Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Adamis Pharmaceuticals (NASDAQ:ADMP) Frequently Asked Questions

Is Adamis Pharmaceuticals a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adamis Pharmaceuticals in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Adamis Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADMP, but not buy additional shares or sell existing shares.
View analyst ratings for Adamis Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Adamis Pharmaceuticals?

Wall Street analysts have given Adamis Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Adamis Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Adamis Pharmaceuticals?

Adamis Pharmaceuticals saw a increase in short interest in the month of July. As of July 15th, there was short interest totaling 11,380,000 shares, an increase of 23.3% from the June 30th total of 9,230,000 shares. Based on an average daily trading volume, of 8,540,000 shares, the short-interest ratio is currently 1.3 days.
View Adamis Pharmaceuticals' Short Interest

When is Adamis Pharmaceuticals' next earnings date?

Adamis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 16th 2021.
View our earnings forecast for Adamis Pharmaceuticals

How were Adamis Pharmaceuticals' earnings last quarter?

Adamis Pharmaceuticals Co. (NASDAQ:ADMP) released its quarterly earnings results on Wednesday, April, 14th. The specialty pharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by $0.18. The specialty pharmaceutical company had revenue of $3.64 million for the quarter. Adamis Pharmaceuticals had a negative net margin of 298.85% and a negative trailing twelve-month return on equity of 176.31%.
View Adamis Pharmaceuticals' earnings history

How has Adamis Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Adamis Pharmaceuticals' stock was trading at $0.4029 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ADMP stock has increased by 192.9% and is now trading at $1.18.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ADMP?

3 brokerages have issued 1-year price objectives for Adamis Pharmaceuticals' stock. Their forecasts range from $1.50 to $1.50. On average, they anticipate Adamis Pharmaceuticals' stock price to reach $1.50 in the next twelve months. This suggests a possible upside of 27.1% from the stock's current price.
View analysts' price targets for Adamis Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Adamis Pharmaceuticals' key executives?

Adamis Pharmaceuticals' management team includes the following people:
  • Dr. Dennis J. Carlo, Pres, CEO & Director (Age 78, Pay $982.81k)
  • Mr. Robert O. Hopkins, Sr. VP of Fin., CFO & Sec. (Age 61, Pay $579.96k)
  • Mr. David J. Marguglio, Sr. VP, Chief Bus. Officer & Director (Age 51)
  • Dr. Ronald B. Moss, Chief Medical Officer (Age 60, Pay $613.65k)
  • Ms. Karen K. Daniels, VP of Operations (Age 68)
  • Mr. David C. Benedicto, Principal Accounting Officer (Age 60)
  • Mr. Mark Flather, Sr. Director of Investor Relations & Corp. Communications
  • Ms. Jennifer C. Suski, Sr. Director of Marketing
  • Mr. Eddie Wabern Glover, Chief Exec. Officer of US Compounding Inc (Age 71)
  • Mr. Robert B. Rothermel, Consultant (Age 77)

Who are some of Adamis Pharmaceuticals' key competitors?

What other stocks do shareholders of Adamis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamis Pharmaceuticals investors own include Trevena (TRVN), Amarin (AMRN), Sorrento Therapeutics (SRNE), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Agile Therapeutics (AGRX) and OPKO Health (OPK).

What is Adamis Pharmaceuticals' stock symbol?

Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP."

How do I buy shares of Adamis Pharmaceuticals?

Shares of ADMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adamis Pharmaceuticals' stock price today?

One share of ADMP stock can currently be purchased for approximately $1.18.

How much money does Adamis Pharmaceuticals make?

Adamis Pharmaceuticals has a market capitalization of $175.69 million and generates $16.53 million in revenue each year. The specialty pharmaceutical company earns $-49,390,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis.

How many employees does Adamis Pharmaceuticals have?

Adamis Pharmaceuticals employs 116 workers across the globe.

What is Adamis Pharmaceuticals' official website?

The official website for Adamis Pharmaceuticals is

Where are Adamis Pharmaceuticals' headquarters?

Adamis Pharmaceuticals is headquartered at 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130.

How can I contact Adamis Pharmaceuticals?

Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-997-2400 or via email at [email protected]

This page was last updated on 7/31/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.